Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.

被引：0
作者：
Felip, Enriqueta
Doger, Bernard
Majem, Margarita
Carcereny, Enric
Krebs, Matthew
Peguero, Julio Antonio
Roxburgh, Patricia
Forster, Martin
Bajaj, Pawan
Clay, Timothy Dudley
Triebel, Frederic
机构：
[1] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[2] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[3] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[4] Hosp Badalona Germans Trias & Pujol, B ARGO Grp Badalona Appl Res Grp Oncol, Catalan Inst Oncol, Med Oncol Dept, Badalona, Spain
[5] Christie NHS Fdn Trust, Manchester, Lancs, England
[6] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[7] Oncol Consultants PA, Dept Res, Houston, TX USA
[8] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[9] UCL Canc Inst, London, England
[10] Univ Coll London Hosp, London, England
[11] Griffith Univ, Brisbane, Qld, Australia
[12] St John God Hosp, Perth, WA, Australia
[13] Immutep, Res & Dev, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3100
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase I/II study of pembrolizumab (P) with gemcitabine (G) in patients (Pts) with previously-treated advanced non-small cell lung cancer (NSCLC): Phase I safety results
    Sanborn, Rachel E.
    Duffy, Regan M.
    Fisher, Brenda K.
    Perlewitz, Kelly Shea
    Redmond, William L.
    Koguchi, Yoshinobu
    Fox, Bernard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients
    Wildiers, Hans
    Armstrong, Anne
    Cuypere, Eveline
    Dalenc, Florence
    Dirix, Luc
    Chan, Steve
    Marme, Frederik
    Schroder, Carolina Pia
    Huober, Jens
    Wagemans, Jill
    Vuylsteke, Peter
    Jacquin, Jean-Philippe
    Brain, Etienne
    Kummel, Sherko
    Papai, Zsuzsanna
    Perjesi, Luca
    Mueller, Christian
    Brignone, Chrystelle
    Triebel, Frederic
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).
    Clarke, Jeffrey Melson
    Wang, Xiaofei F.
    Gu, Lin
    Stevenson, Marvaretta Miesha
    Stinchcombe, Tom
    Ramalingam, Sundhar
    Antonia, Scott Joseph
    Shariff, Afreen
    Garst, Jennifer
    Crawford, Jeffrey
    Ready, Neal E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Weekly paclitaxel, carboplatin, and bexarotene for the treatment of patients with advanced non-small cell lung cancer: Efficacy results from a phase I/II study.
    Petty, WJ
    Dragnev, KH
    Black, WC
    Cole, BF
    Hammond, S
    Williams, I
    Dmitrovsky, E
    Rigas, JR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 681S - 681S
  • [45] Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
    Paz-Ares, Luis G.
    Luft, Alexander
    Tafreshi, Ali
    Gumus, Mahmut
    Mazieres, Julien
    Hermes, Barbara
    Senler, Filiz Cay
    Fulop, Andrea
    Rodriguez-Cid, Jeronimo
    Sugawara, Shunichi
    Cheng, Ying
    Novello, Silvia
    Halmos, Balazs
    Yue Shentu
    Kowalski, Dariusz
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.
    Nguyen, Ryan Huu-Tuan
    Notardonato, Lucia
    Hulbert, Alicia
    Mallisetty, Apurva
    Weinberg, Frank
    Rubinstein, Israel
    Juson, Irene
    Chan, Cindy
    Liu, Li C.
    Chen, Zhengjia
    Feldman, Lawrence Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Icotinib and whole brain radiotherapy (WBRT) for patients with brain metastases from non-small cell lung cancer (NSCLC): Preliminary results of a phase II study.
    Yun, Fan
    Huang, Zhiyu
    Gong, Lei
    Yu, Haifeng
    Yang, Haiyan
    Lu, Maio Lu
    Mao, Weimin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Symptom-based Patient-reported Outcome Results from a Phase II Study of Sunitinib in Patients With Non-small Cell Lung Cancer and Brain Metastases
    Cella, D.
    Abrey, L.
    Novello, S.
    Wang, J.
    Usari, T.
    Mundayat, R.
    Thall, A.
    Chao, R. C.
    Scagliotti, G.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S540 - S541
  • [49] Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Shen, Qin
    Cho, Lillian
    Stjepanovic, Neda
    Boklage, Susan
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [50] Results from short-term CT assessments in patients (pts) with advanced poor performance status non-small cell lung cancer (NSCLC) receiving pemetrexed in a phase II trial
    Zinner, R.
    Herbst, R. S.
    Fossella, F. V.
    Johnson, F. M.
    Karp, D. D.
    Kies, M. S.
    Heymach, J. V.
    Price, J. S.
    Lippman, S. M.
    Erasmus, J., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345